Clinical Trial Update: Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients [Phase 2]

View source ↗

Summary

The document reports the completion of an open-label Phase 2 rollover study evaluating levosimendan in patients with pulmonary hypertension due to heart failure…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Pulmonary Hypertension
• Right-sided Heart Failure

Drugs mentioned

• Levosimendan (levosimendan)

Snippet

Sponsor: Tenax Therapeutics, Inc. | Conditions: Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction | Phase 2 | Status: COMPLETED | Results posted: 2026-04-22